Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy

[1] de The G(1993)An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retrovir 9 381-386

[2] Bomford R(2007)Human T-lymphotropic virus 1: recent knowledge about an ancient infection Lancet Infect Dis 7 266-281

[3] Verdonck K(1990)The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I J Acquir Immune Defic Syndr 3 1096-1101

[4] Gonzalez E(2000)A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 1586-1593

[5] Van Dooren S(2002)Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 1349-1356

[6] Kaplan JE(2005)Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462-2476

[7] Osame M(1990)Spontaneous reactivation in chronic hepatitis B: patterns and natural history J Clin Gastroenterol 12 562-568

[8] Kubota H(2012)Current prevalence of HTLV-1 in Japan as determined by screening of blood donors J Med Virol 84 327-335

[9] Bathon JM(2016)Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden BMJ (Clinical research ed) 352 i262-650

[10] Martin RW(2016)Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan Modern Rheumatol Japan Rheum Assoc 26 642-361

[1] de The G(1993)An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retrovir 9 381-386

[2] Bomford R(2007)Human T-lymphotropic virus 1: recent knowledge about an ancient infection Lancet Infect Dis 7 266-281

[3] Verdonck K(1990)The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I J Acquir Immune Defic Syndr 3 1096-1101

[4] Gonzalez E(2000)A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 1586-1593

[5] Van Dooren S(2002)Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha N Engl J Med 346 1349-1356

[6] Kaplan JE(2005)Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462-2476

[7] Osame M(1990)Spontaneous reactivation in chronic hepatitis B: patterns and natural history J Clin Gastroenterol 12 562-568

[8] Kubota H(2012)Current prevalence of HTLV-1 in Japan as determined by screening of blood donors J Med Virol 84 327-335

[9] Bathon JM(2016)Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden BMJ (Clinical research ed) 352 i262-650

[10] Martin RW(2016)Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan Modern Rheumatol Japan Rheum Assoc 26 642-361